ReviewJournal of pharmaceutical analysis2026
Antibody screening for tumor and immune hotspot targets: The frontier of new methods and technologies.
Review in Journal of pharmaceutical analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multidisciplinary cutting-edge technologies accelerating target-based drug discovery.Journal of pharmaceutical analysis · 2026Article
- Artificial intelligence in vaccine development: applications, implementation, and future directions.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advancements in tumor immunotherapy highlight the significant potential of antibody drugs, a key category of biological agents, for treating cancer and autoimmune diseases. This paper begins by defining and classifying key targets in tumor immunity, as well as discussing their structural and functional characteristics. Subsequently, it elaborates on innovative technologies for antibody drug screening, which, when integrated with contemporary molecular biology, biotechnology, and computational biology, have substantially enhanced the efficiency and accuracy of target identification and antibody drug screening processes. Despite the promising prospects of tumor immunotherapy, certain limitations persist in its practical implementation. In conclusion, this paper offers a comprehensive examination of the cutting-edge developments in tumor immunotherapy, focusing on the aspects of tumor immunotherapy itself, critical targets for immunotherapy, and novel technologies and methodologies for antibody screening. This analysis is crucial for advancing the field of tumor immunotherapy and for enhancing both therapeutic efficacy and safety. Furthermore, research and development (R&D) of antibody drugs in other domains, such as autoimmune and inflammatory diseases, can benefit from it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.